Naloxone Statewide Standing Order. Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties

Size: px
Start display at page:

Download "Naloxone Statewide Standing Order. Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties"

Transcription

1 Naloxone Statewide Standing Order Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties

2 Objectives Review the US & NC trends on opioid overdose Understand key elements of NC s statewide standing order for naloxone Identify patients at high risk of overdose and candidates for naloxone

3 Overdose Deaths in the US From , 500,000 drug overdose (OD) deaths Surpassed motor vehicle accidents - in 2014, ~ 1.5X more drug OD deaths vs deaths from MV crashes In 2014, opioids (Rx & heroin) were involved in 28,647 deaths, or 61% of all OD Rate of opioid OD has tripled since The 2014 data US opioid OD epidemic 2 trends a 15-year increase in overdose deaths involving prescription opioid pain relievers recent surge in illicit opioid overdose deaths, driven largely by heroin. 44 people in the US die EVERY DAY from an Rx opioid overdose (CDC) 78 people in the US die EVERY DAY from an OPIOID overdose MMWR - Increases in Drug and Opioid Overdose Deaths United States,

4 Deaths per 100,000 population Death Rates* for Three Selected Causes of Injury, North Carolina, Motor Vehicle Traffic (Unintentional) Drug Poisoning (All Intents) Firearm (All Intents) Year *Per 100,00, age-adjusted to the 2000 U.S. Standard Population National Vital Statistics System, multiple cause dataset Source: Death files, , CDC WONDER Analysis by Injury Epidemiology and Surveillance Unit 4

5 Number of deaths 1,400 1,200 1, Medication or Drug Overdose Deaths by Intent North Carolina Residents, All intents Unintentional Self-inflicted Undetermined Assault 1,306 1, Source: N.C. State Center for Health Statistics, Vital Statistics-Deaths, Analysis by Injury Epidemiology and Surveillance Unit Medication or drug overdose: X40-X44, X60-X64, Y10-Y14, X85 5

6 Substances Contributing to Medication or Drug Overdose Deaths North Carolina Residents, Prescrip on Opioid Cocaine Heroin 684 Number of deaths Source: N.C. State Center for Health Statistics, Vital Statistics-Deaths, Analysis by Injury Epidemiology and Surveillance Unit 6

7 NC Heroin Deaths: * % increase from 2010 to * Source: N.C. State Center for Health Statistics, Vital Statistics-Deaths, * *2015 data are provisional and likely increase as cases are finalized Analysis by Injury Epidemiology and Surveillance Unit 7

8 Heroin Hosp. and ED Overdoses: , From 2010 to 2014 a 429% increase for ED visits Source: N.C. State Center for Health Statistics, Vital Statistics-Hospital Discharge NC DETECT- Statewide ED Visit data, Analysis by Injury Epidemiology and Surveillance Unit ED Hosp

9 NC Statewide Standing Order This standing order signed by the North Carolina (N.C.) State Health Director authorizes any pharmacist practicing in the state of N.C. and licensed by the N.C. Board of Pharmacy to dispense the following Naloxone products to persons as directed below 9

10 Elements of the NC Statewide Standing Order Eligible candidates Naloxone products that can be dispensed under standing order Directions for use Refills: PRN Contraindications: A history of known hypersensitivity to Naloxone or any of its components Patient Education Notification of Participation Executed/signed standing order can be found on

11

12 Naloxone: Pharmacology Opioid Naloxone Opioid receptor on brain

13 Naloxone: Basics Approved by the FDA in 1971 (available for lay use since 1996) No psychoactive effects No street value (because it causes withdrawal NOT EUPHORIA) No abuse potential : not known to produce tolerance or physical/psychological dependence Naloxone rarely has any effect on someone not taking opioids Not a controlled substance Administration routes IM & Intranasal routes : onset 3-5 minutes (give 2 nd dose if no response) PO (NOT absorbed - use as abuse deterrent) ; IV hospital, SC month shelf life

14 Naloxone: Safety Well-established body of evidence of its safety and efficacy Adverse reactions are rare, however, when they occur they are often secondary to narcotic withdrawal (pain, sweating, agitation, etc) Typically occurs within minutes Subsides within two hours Other rare side effects include: Increased blood pressure and heart rate Arrhythmia Nasal Spray: premarketing trials showed transient hypertension, musculoskeletal pain, HA, nasal dryness/congestion/edema/inflammation

15 Naloxone: Duration of Action Anywhere from 30 to 120 minutes (shorter than many opioids) May not outlast effects of long-acting or ER opioids NOT meant to substitute going to the ED; it just buys more time AND helps prevents complications

16 Which Patients Are Eligible as Defined By Standing Order? Persons who voluntarily request Naloxone and are at risk of experiencing an opiate-related overdose, including, but not limited to: 1. Current/history of heroin or nonmedical opioid use 2. History of emergency medical care involving opioid poisoning/intoxication/overdose 3. Persons with a high dose opioid prescription >50 morphine mg equivalents (MME) per day 4. Persons with an opioid prescription and known or suspected concurrent alcohol use 5. Recent discharge from opioid detox or abstinence-based program

17 Which Patients Are Eligible as Defined By Standing Order (continued)? 6. Patients entering methadone maintenance treatment (addiction or pain) 7. Persons with opioid prescription and smoking/copd or other respiratory illness or obstruction 8.Persons with an opioid prescription who also suffer from renal dysfunction, hepatic disease, cardiac disease, HIV/AIDS 9. Persons who may have difficulty accessing emergency medical services 10.Persons enrolled in prescription lock in programs

18 Which Patients Are Eligible as Defined By Standing Order? Persons who voluntarily request Naloxone and are the family member or friend of a person at risk of experiencing an opiaterelated overdose. Persons who voluntarily request Naloxone and are in the position to assist a person at risk of experiencing an opiate-related overdose.

19 Which Other Patients Could Be Considered for Naloxone? Concurrent benzodiazepine prescription with opioid prescription Also sleep aids, muscle relaxants Multiple physicians and pharmacies Methadone Has been associated with disproportionate numbers of overdose deaths relative to the frequency with which it is prescribed for pain Involved in twice as many single-drug deaths as any other prescription opioid CDC Guideline for Prescribing Opioids for Chronic Pain United States,

20 Naloxone Just in Case Fairfield, Connecticut: 5 year old stepped (barefoot) on a fentanyl patch left on the kitchen floor. By the time he got emergency medical attention, it was too late, and he died of respiratory depression Burlington, NC: High School football player was sore after a Friday night game. Took his Grandma s methadone and died Pain medications are the single most frequent cause of pediatric fatalities reported to Poison Control. National Capitol Poison Center:

21 Intramuscular Naloxone IM kits contents: 2 naloxone 0.4 mg/ml (1 ml) vials 2 IM syringes with alcohol swabs step-by-step instructions for responding to an opioid overdose directions for naloxone administration Gloves, mask optional Advantages: Least expensive option; NCHRC distributes Covered by most insurances Disadvantages: Some people not comfortable with giving injections

22 Intramuscular Naloxone Evzio Approved 4/3/14 Pre-filled auto-injector (IM/SC) Each Evzio contains a single dose of naloxone; do not reuse Each carton contains 2 autoinjectors Electronic voice instructions Advantages: Easy to use, instructions given Disadvantages: MOST expensive product NC Medicaid non-preferred Cannot be used with statewide standing order

23 Intranasal Naloxone (Generic) 2 mg/2ml prefilled syringes Requires nasal atomizer device for IN use Project Lazarus Kits/Generic IN Kits 2 naloxone 2 mg/2 ml prefilled syringes (filled by pharmacy and placed into kit) 2 atomizers Step-by-step instructions for responding to an opioid overdose Directions for naloxone administration Advantages: Needleless Slight cost advantage over branded IN product Disadvantages: Complex assembly procedure

24 Narcan Nasal Spray FDA approved 11/18/15, Released 2/26/16 Ready to go no assembly required 4mg dose 2x higher dose than generic IN formulation Advantages: Easy to use and no assembly required NC Medicaid Preferred as of 4/1/16 and many private/medicare Part D plans covering AWP $150 for 2 sprays Non-profit pricing $75 per 2 devices Disadvantages: Still somewhat expensive for uninsured

25 Patient Education Requirements For Standing Order Risk Factors Signs of an overdose Overdose Response Steps Naloxone administration education

26 CPESN Naloxone Service Set Dispense naloxone in accordance with the statewide North Carolina standing order, and provide the additional enhanced services: The pharmacist will talk with the patient about the aspects of their prescription medication and other substance use that increase their risk for overdose Utilization of the Controlled Substance Reporting System (As needed based upon the judgment of the pharmacist) Provide enhanced education to the patient and others on administration of naloxone Educate patients about safe opioid and benzodiazepine storage in the home Communicate with prescriber(s) and/or primary care provider to make them aware of naloxone dispensing As needed, participate in CPESN naloxone service set education provided by CCNC

27 Wake County

28 Johnston County

29 Medications Disposal Sites Wake County Holly Park Pharmacy 3004 Wake Forest Rd Raleigh, NC (919) Johnston County Beddingfield Drugs 95 Springbrook Ave Ste 101 Clayton, NC (919)

30 Resources NC Specific Site for statewide standing order College of Psychiatric and Neurologic Pharmacists NC Board of Pharmacy FAQs, Standing Orders, Protocols df Videos, ordering information, prescription forms, etc: NC Harm Reduction Coalition

31 Questions? 31

October 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies

October 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies October 20, 2016 Scott K. Proescholdbell, MPH Opioid Overdose and North Carolina s Public Health and Prevention Strategies Deaths per 100,000 population Death Rates* for Three Selected Causes of Injury,

More information

Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals

Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Clint Ross, PharmD, BCPP Clinical Pharmacy Specialist Psychiatry Residency Program Director Psychiatric Pharmacy Medical University

More information

Naloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no

Naloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no THE SOUTH CAROLINA BOARD OF MEDICAL EXAMINERS AND THE SOUTH CAROLINA BOARD OF PHARMACY S JOINT PROTOCOL TO INITIATE DISPENSING OF NALOXONE HCI WITHOUT A PRESCRIPTION This joint protocol authorizes any

More information

Opioid Harm Reduction

Opioid Harm Reduction Opioid Harm Reduction Lucas G. Hill, PharmD Clinical Assistant Professor, The University of Texas at Austin College of Pharmacy Clinical Pharmacist, CommUnityCare FQHCs Director, Operation Naloxone Mark

More information

Naloxone Information for Community Pharmacies in Georgia: What You Need to Know

Naloxone Information for Community Pharmacies in Georgia: What You Need to Know Naloxone Information for Community Pharmacies in Georgia: What You Need to Know Your pharmacy may start receiving an increased volume of prescriptions for naloxone (Narcan ) due to legal changes in 2014.

More information

Naloxone Standardized Procedures Illinois Departments of DFPR, DPH & DHS Opioid Antagonist Initiative

Naloxone Standardized Procedures Illinois Departments of DFPR, DPH & DHS Opioid Antagonist Initiative Naloxone Standardized Procedures Illinois Departments of DFPR, DPH & DHS Opioid Antagonist Initiative Background: In September 2015, Illinois passed a new law, PA99-0480, expanding access to the opioid

More information

OPIOIDS IN JACKSON COUNTY A PUBLIC HEALTH PERSPECTIVE OPIOID AWARENESS COUNTY LEADERSHIP FORUM SHELLEY CARRAWAY, HEALTH DIRECTOR DATE

OPIOIDS IN JACKSON COUNTY A PUBLIC HEALTH PERSPECTIVE OPIOID AWARENESS COUNTY LEADERSHIP FORUM SHELLEY CARRAWAY, HEALTH DIRECTOR DATE OPIOIDS IN JACKSON COUNTY A PUBLIC HEALTH PERSPECTIVE OPIOID AWARENESS COUNTY LEADERSHIP FORUM SHELLEY CARRAWAY, HEALTH DIRECTOR DATE LOCAL HEALTH DIRECTOR REGIONS For counties with low counts, regional

More information

Opioid Prescription and Illicit Drug Overdoses: On the Rise

Opioid Prescription and Illicit Drug Overdoses: On the Rise Opioid Prescription and Illicit Drug Overdoses: On the Rise Cindy Haynes, MSA-PA, CHES Chronic Pain Program Coordinator Northern Piedmont Community Care Duke Division of Community Health Objectives Define

More information

The Opioid Epidemic: The State of the State

The Opioid Epidemic: The State of the State JOINT LEGISLATIVE COMMITTEE ON HEALTH AND HUMAN SERVICES The Opioid Epidemic: The State of the State Dr. Mandy Cohen, Dr. Susan Kansagra Department of Health and Human Services Nov. 14, 2017 3 PEOPLE DIE

More information

Opioid Data for Local Governments in North Carolina

Opioid Data for Local Governments in North Carolina Opioid Data for Local Governments in North Carolina Mary Beth Cox, Stacy Taylor, and Adam Lovelady October 10, 2018 Speakers Adam Lovelady Associate Professor UNC School of Government Mary Beth Cox Substance

More information

Journal Club: Naloxone Programs in the Community and Their Success to Decrease Overdoses from Opioids

Journal Club: Naloxone Programs in the Community and Their Success to Decrease Overdoses from Opioids Journal Club: Naloxone Programs in the Community and Their Success to Decrease Overdoses from Opioids Emily Junck, MD Hayes Wong, MD Paul Freeman, MD Special Guest: Caleb Banta-Green, PhD, MPH, MSW Special

More information

May 25, Drug Overdose Update & Response: Combatting Opioid Overdose

May 25, Drug Overdose Update & Response: Combatting Opioid Overdose May 25, 2017 Drug Overdose Update & Response: Combatting Opioid Overdose Overview The Problem -Overdose in North Carolina (and a little nationally) -Other associated health threats PDAAC-NC s Response

More information

Naloxone Standing Order for Opioid Overdose

Naloxone Standing Order for Opioid Overdose Naloxone Standing Order for Opioid Overdose By: Christine Trusky, PharmD Candidate 2016, Wilkes University Continuing Education Activity Details: Activity Type: Knowledge-based Target Audience: Pharmacists

More information

Unintentional Poisonings: Public Health Response Joint Legislative Health Care Oversight Committee

Unintentional Poisonings: Public Health Response Joint Legislative Health Care Oversight Committee Unintentional Poisonings: Public Health Response Joint Legislative Health Care Oversight Committee Dr. Ruth Petersen Chronic Disease and Injury Section Division of Public Health Oct 12, 2010 In 1999, the

More information

Drug Class Review: Opioid Reversal Agents

Drug Class Review: Opioid Reversal Agents Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

NALOXONE: HEALTHCARE PROFESSIONALS TRAINING GUIDE FOR ADMINISTRATION AND DISPENSING

NALOXONE: HEALTHCARE PROFESSIONALS TRAINING GUIDE FOR ADMINISTRATION AND DISPENSING NALOXONE: HEALTHCARE PROFESSIONALS TRAINING GUIDE FOR ADMINISTRATION AND DISPENSING Kaitlyn Bernard, PharmD PGY-1 Pharmacy Practice Resident November 18, 2017 Objectives Explain the impact of the opioid

More information

Naloxone: What You Need to Know About Overdose Reversal In the Midst of an Opioid Epidemic

Naloxone: What You Need to Know About Overdose Reversal In the Midst of an Opioid Epidemic Naloxone: What You Need to Know About Overdose Reversal In the Midst of an Opioid Epidemic Kyle Troksa, Pharm.D., AE-C PGY1 Resident Community Medical Center March 4th, 2018 Conflicts of Interest No conflicts

More information

Community Pharmacy Distribution of Naloxone

Community Pharmacy Distribution of Naloxone Community Pharmacy Distribution of Naloxone College of Pharmacists of BC BC Centre for Disease Control Harm Reduction Program Sponsored in part by the BC Ministry of Health What is Naloxone? Naloxone is

More information

Protocol For: Personally Furnishing Naloxone. Update Log

Protocol For: Personally Furnishing Naloxone. Update Log Protocol For: Personally Furnishing Naloxone Update Log Updated By: Reason for Update: Date: Approved By: K. Benick RN Original draft 6/7/16 Pam Butler Protocol: Personally Furnishing Naloxone_Morrow County

More information

Steve Alsum. The Grand Rapids Red Project. (616)

Steve Alsum. The Grand Rapids Red Project. (616) Steve Alsum The Grand Rapids Red Project steve@redproject.org (616) 456-9063 Red Project Basics Overdose Epidemiology Naloxone Distribution Overview Locally And In Michigan Innovative National Models A

More information

NARCAN: THE HISTORY, APPLICATIONS AND FUTURE

NARCAN: THE HISTORY, APPLICATIONS AND FUTURE NARCAN: THE HISTORY, APPLICATIONS AND FUTURE TABLE OF CONTENTS 3 Intro 4 What is Naloxone? 8 How Naloxone is Administered 12 Where to Find Narcan in California The United States accounts for about five

More information

How to Prevent an Opioid Overdose

How to Prevent an Opioid Overdose How to Prevent an Opioid Overdose MEDICAL CARE PROVIDERS: Providers can help reduce the likelihood of an opioid overdose by identifying patients who are at increased risk of opioid-induced respiratory

More information

Guidelines for Healthcare Providers

Guidelines for Healthcare Providers Iredell County Opioid Epidemic: Guidelines for Healthcare Providers February 25, 2017 Nidhi Sachdeva, MPH NC Division of Public Health, Injury and Violence Prevention 2 Number of deaths Medication or Drug

More information

NARCAN? YOU CAN!: A LEGISLATIVE & CLINICAL UPDATE ON NALOXONE

NARCAN? YOU CAN!: A LEGISLATIVE & CLINICAL UPDATE ON NALOXONE NARCAN? YOU CAN!: A LEGISLATIVE & CLINICAL UPDATE ON NALOXONE Stephanie Nichols, PharmD, BCPS, BCPP Associate Professor, Husson University Nicholss@husson.edu Why did you become a pharmacy professional?

More information

Naloxone and Combating the Opioid Epidemic

Naloxone and Combating the Opioid Epidemic Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Take Home Naloxone: What Pharmacists Need to Know

Take Home Naloxone: What Pharmacists Need to Know Take Home Naloxone: What Pharmacists Need to Know Sheri L. Fandrey, BSP, PhD Knowledge Exchange Lead Manitoba Addictions Knowledge Exchange Conflict of Interest/Disclosure Dr. Sheri Fandrey Has no conflicts

More information

Reducing opioid overdose mortality: role of communityadministered

Reducing opioid overdose mortality: role of communityadministered Reducing opioid overdose mortality: role of communityadministered naloxone Vennus Ballen, MD, MPH; Lara Maldjian, MPH New York City Department of Health and Mental Hygiene Clinical Director s Network (CDN)

More information

Anyone Can Become Addicted. Anyone.

Anyone Can Become Addicted. Anyone. Anyone Can Become Addicted. Anyone. PAStop.org Family Toolkit Seeking Drug Abuse Treatment: Know What to Ask Trying to identify the right treatment programs for a loved one can be a difficult process.

More information

Naloxone Non-Patient Specific Prescription and Pharmacist Dispensing Protocol, New York City

Naloxone Non-Patient Specific Prescription and Pharmacist Dispensing Protocol, New York City Section 1: Purpose Naloxone Non-Patient Specific Prescription and Pharmacist Dispensing Protocol, New York City As some of health care s most accessible practitioners, pharmacists are uniquely positioned

More information

Opioid Overdose Education and Naloxone Distribution

Opioid Overdose Education and Naloxone Distribution Opioid Overdose Education and Naloxone Distribution Emily Stoukides, PharmD PGY-2 Ambulatory Care Pharmacy Resident Nicole Brunet, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health Disclosures Emily

More information

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Svetla Slavova, PhD Sara LaMantia, MS Terry Bunn, PhD Tracey Corey, MD 2016 Safe States Annual Meeting April 13, 2016, Albuquerque,

More information

Opioid Safety: Focus on Furnishing Naloxone

Opioid Safety: Focus on Furnishing Naloxone Opioid Safety: Focus on Furnishing Naloxone A GUIDE FOR CALIFORNIA COMMUNITY PHARMACISTS Talia Puzantian, PharmD, BCPP Associate Professor Keck Graduate Institute School of Pharmacy James J. Gasper, PharmD,

More information

Revised 16 February, of 7

Revised 16 February, of 7 341 State Street Suite G Madison, WI 53703 ph: (608) 251 4454 f: (608) 251 3853 6333 University Avenue, Middleton WI 53562 ph: (608) 310 5389 f: (608) 285 9603 INTRANASAL OR INTRAMUSCULAR NALOXONE PROTOCOL:

More information

TITLE AUTHORS. Lucas G. Hill, PharmD The University of Texas at Austin College of Pharmacy

TITLE AUTHORS. Lucas G. Hill, PharmD The University of Texas at Austin College of Pharmacy TITLE Naloxone Counseling for Harm Reduction and Patient Engagement AUTHORS Lucas G. Hill, PharmD The University of Texas at Austin College of Pharmacy Marianne E. Koenig, PharmD UPMC St. Margaret Family

More information

OVERDOSE IN UTAH PREVENTION AND RESPONSE. Meghan Balough, MPH Heather Bush, B.S. Suicide Conference October 6, 2017

OVERDOSE IN UTAH PREVENTION AND RESPONSE. Meghan Balough, MPH Heather Bush, B.S. Suicide Conference October 6, 2017 OVERDOSE IN UTAH PREVENTION AND RESPONSE Meghan Balough, MPH Heather Bush, B.S. Suicide Conference October 6, 2017 Questions How many people have known someone who has experienced an overdose? How many

More information

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction

More information

Steve Alsum. The Grand Rapids Red Project (616)

Steve Alsum. The Grand Rapids Red Project (616) Steve Alsum The Grand Rapids Red Project steve@redprojectgr.org (616) 456-9063 Red Project: Mission/History/Programs Epidemiology of Overdose Overdose Prevention in Grand Rapids National Efforts Moving

More information

NALOXONE LEARNING ABOUT NALOXONE COULD SAVE A LIFE

NALOXONE LEARNING ABOUT NALOXONE COULD SAVE A LIFE NALOXONE LEARNING ABOUT NALOXONE COULD SAVE A LIFE WHAT IT IS WHAT IT IS NARCAN (naloxone HCl) Nasal Spray is the first and only FDA-approved nasal form of naloxone for the emergency treatment of a known

More information

Naloxone for Emergency Administration: A 2017 Update On FDA Guidance

Naloxone for Emergency Administration: A 2017 Update On FDA Guidance Naloxone for Emergency Administration: A 2017 Update On FDA Guidance Nathan A. Painter, PharmD, CDE Associate Clinical Professor University of California San Diego Skaggs School of Pharmacy and Pharmaceutical

More information

Law Enforcement Naloxone Training Florida Department of Children and Families. Office of Substance Abuse and Mental Health

Law Enforcement Naloxone Training Florida Department of Children and Families. Office of Substance Abuse and Mental Health Protecting, Leading, Uniting Since 1893 Law Enforcement Naloxone Training Florida Department of Children and Families Office of Substance Abuse and Mental Health 1. Learn how to recognize and respond to

More information

Sierra Sacramento Valley EMS Agency

Sierra Sacramento Valley EMS Agency Sierra Sacramento Valley EMS Agency BLS IN NALOXONE ADMINISTRATION OPTIONAL SKILL (UPDATED 06/2017) Acknowledgement: Siskiyou County SO - source of some slide content In order for PSFA, EMR or EMT personnel

More information

Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices

Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices August 25, 2017 Presented by Michael Crooks, PharmD. Medication Safety and Care Coordination Task Lead 8/28/2017

More information

3/19/18. Background. School Substance Use Problem: Naloxone and How It Will Be Implemented in Schools. Background

3/19/18. Background. School Substance Use Problem: Naloxone and How It Will Be Implemented in Schools. Background School Substance Use Problem: Naloxone and How It Will Be Implemented in Schools Rodrick J. Marriott, PharmD Director, Drug Control Division Background Background Overdose deaths involving prescription

More information

Role of the Pharmacist: Naloxone Training. Kathleen Besinque, Pharm.D.,MSEd., FASHP, FCPhA Loma Linda University School of Pharmacy

Role of the Pharmacist: Naloxone Training. Kathleen Besinque, Pharm.D.,MSEd., FASHP, FCPhA Loma Linda University School of Pharmacy Role of the Pharmacist: Naloxone Training Kathleen Besinque, Pharm.D.,MSEd., FASHP, FCPhA Loma Linda University School of Pharmacy Disclosure Kathleen Besinque Nothing to disclose. Objectives: After attending

More information

Changing Course: statewide efforts to combat the opioid epidemic in California

Changing Course: statewide efforts to combat the opioid epidemic in California Changing Course: statewide efforts to combat the opioid epidemic in California Kelly Pfeifer, MD kpfeifer@chcf.org April 26, 2018 State of Reform conference STAT Special Report: 52 weeks, 52 faces Obituaries

More information

Opioid Use in Youth. Amy Yule M.D. March 2,

Opioid Use in Youth. Amy Yule M.D. March 2, Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin

More information

Opioid Safety: Focus on Furnishing Naloxone A GUIDE FOR CALIFORNIA COMMUNITY PHARMACISTS

Opioid Safety: Focus on Furnishing Naloxone A GUIDE FOR CALIFORNIA COMMUNITY PHARMACISTS Opioid Safety: Focus on Furnishing Naloxone A GUIDE FOR CALIFORNIA COMMUNITY PHARMACISTS Purpose of this guide Community pharmacists are uniquely poised to engage in efforts to reduce opioid misuse and

More information

POWER TO HELP REVERSE AN OPIOID OVERDOSE

POWER TO HELP REVERSE AN OPIOID OVERDOSE POWER TO HELP REVERSE AN OPIOID OVERDOSE FDA APPROVED Concentrated 4 mg dose Needle-free; no assembly required Designed for ease-of-use in the community setting Requires no specialized training* Not a

More information

Potential Solutions to Epidemic Substance Abuse in US and Europe

Potential Solutions to Epidemic Substance Abuse in US and Europe Potential Solutions to Epidemic Substance Abuse in US and Europe Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center, Denver Health 1 Professor, University of Colorado School of Medicine

More information

Opioid epidemic and PEHP

Opioid epidemic and PEHP Opioid epidemic and PEHP Agenda Overview of opioid crisis Utah perspective PEHP: clinical interventions Impact of interventions Why are we here? In the 1990s, the medical establishment came to believe

More information

Dosage. Hospira Mylan Amphastar Amphastar syringe Teleflex (nasal adapter) 0.4 mg/ml 4 mg/10 ml. 1mg/mL (2mg/2mL) Nov (b)(2) Narcan Nasal

Dosage. Hospira Mylan Amphastar Amphastar syringe Teleflex (nasal adapter) 0.4 mg/ml 4 mg/10 ml. 1mg/mL (2mg/2mL) Nov (b)(2) Narcan Nasal August 2016 DoD Drug Class Review: Alcohol Deterrents Narcotic Antagonists Page 1 of 6 Alcohol Deterrents Narcotic Antagonists Narcotic Antagonists Overview Drug overdose accounts for the leading cause

More information

The Opioid Epidemic: Overdose Data in NYC

The Opioid Epidemic: Overdose Data in NYC The Opioid Epidemic: Overdose Data in NYC Sindhu Shamasunder, MPH Bureau of Alcohol and Drug Use Prevention, Care and Treatment NYC Department of Health and Mental Hygiene The burden of drug overdose Nationally,

More information

The Missouri Opioid-Heroin Overdose Prevention and Education (MO-HOPE) Project Mission: to reduce opioid overdose deaths in Missouri through expanded

The Missouri Opioid-Heroin Overdose Prevention and Education (MO-HOPE) Project Mission: to reduce opioid overdose deaths in Missouri through expanded The Missouri Opioid-Heroin Overdose Prevention and Education (MO-HOPE) Project Mission: to reduce opioid overdose deaths in Missouri through expanded access to naloxone, overdose education, prevention,

More information

Unintentional Poisonings: From Data to Action Joint Legislative Health Care Oversight Committee

Unintentional Poisonings: From Data to Action Joint Legislative Health Care Oversight Committee Unintentional Poisonings: From Data to Action Joint Legislative Health Care Oversight Committee Dr. Ruth Petersen and Scott Proescholdbell, MPH Chronic Disease and Injury Section Division of Public Health

More information

Prescribing Naloxone to Patients for Overdose Reversal

Prescribing Naloxone to Patients for Overdose Reversal Prescribing Naloxone to Patients for Overdose Reversal Module Author: Julie Kmiec, DO Assistant Professor of Psychiatry, University of Pittsburgh School of Medicine Addiction Psychiatry - Western Psychiatric

More information

Drug Overdose Prevention Program (DOPP)

Drug Overdose Prevention Program (DOPP) Drug Overdose Prevention Program (DOPP) GUIDELINES FOR IMPLEMENTATION [Type a quote from the documen T or the s ummary of an interesting p oint. You can position the text box anywhere in the document.

More information

Six Years of Opioid-Involved Accidental and Undetermined Fatalities among Connecticut Residents,

Six Years of Opioid-Involved Accidental and Undetermined Fatalities among Connecticut Residents, Six Years of Opioid-Involved Accidental and Undetermined Fatalities among Connecticut Residents, 2009-2014 Lauretta E. Grau, Russell Skip Barbour, and Shawn M. Lang Background Heroin Deaths FDA efforts

More information

OPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN

OPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN OPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN ANTOINETTE BROWN, RPH LAUREL RAMER, 2019 PHARMD CANDIDATE 2018 WYOMING CONFERENCE ON AGING LARAMIE, WY OCTOBER 3, 2018 OBJECTIVES 1. Understand the

More information

White Paper on. Prescription Drug Abuse

White Paper on. Prescription Drug Abuse White Paper on Prescription Drug Abuse October 22, 2014 Table of Contents: I. Introduction II. Scope of the Problem III. Most Common Drugs Involved in Overdoses IV. Efforts in Tennessee V. Prescription

More information

Addressing the Opioid Epidemic through a Public Health Lens

Addressing the Opioid Epidemic through a Public Health Lens Addressing the Opioid Epidemic through a Public Health Lens MONICA BHAREL, MD, MPH MASSACHUSETTS COMMISSIONER OF PUBLIC HEALTH VISION Optimal health and well-being for all people in Massachusetts, supported

More information

Clinical Policy: Naloxone (Evzio) Reference Number: CP.PMN.139 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid

Clinical Policy: Naloxone (Evzio) Reference Number: CP.PMN.139 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid Clinical Policy: Naloxone (Evzio) Reference Number: CP.PMN.139 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of

More information

Pharmacist Learning Objectives

Pharmacist Learning Objectives Opioid Overdose Education and Naloxone Distribution Keith Thornell, Pharm.D. Clinical Pharmacist Co-Occurring Disorders Pain Clinic NM Veterans Affairs Health Care System richard.thornell@va.gov 1 Pharmacist

More information

Advancing Addiction Science to Address the Opioid Crisis

Advancing Addiction Science to Address the Opioid Crisis Advancing Addiction Science to Address the Opioid Crisis National Institute on Drug Abuse Bringing the full power of science to bear on drug abuse and addiction Nora D. Volkow, M.D. Director National Institute

More information

Drug Overdose in New Mexico

Drug Overdose in New Mexico Drug Overdose in New Mexico Behavioral Health Collaborative January 8, 2015 Jim Davis, MA Drug Epidemiologist New Mexico Department of Health Deaths per 100,000 persons 30.0 Drug Overdose Death Rates New

More information

2/20/2017 NALOXONE PRESCRIPTIONS FOR OVERDOSE: OUTSIDE OF MISUSE AND ABUSE DISCLOSURES LEARNING OBJECTIVES

2/20/2017 NALOXONE PRESCRIPTIONS FOR OVERDOSE: OUTSIDE OF MISUSE AND ABUSE DISCLOSURES LEARNING OBJECTIVES NALOXONE PRESCRIPTIONS FOR OVERDOSE: OUTSIDE OF MISUSE AND ABUSE Brett Badgley Snodgrass FNP-C, CPE, FACPP, FAANP Consultant/Independent Contractor: McNeil Pharmaceuticals, Purdue Pharmaceuticals Speaker's

More information

Be courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off.

Be courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off. 1 2 EMT OPTIONAL SKILL Naloxone Intranasal Cell Phones and Pagers Be courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off. 3 4 5 6 Course Outline Introduction

More information

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. DISPENSING OR SELLING NALOXONE Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. UPDATED ON: April 21, 2017 Purpose The intent of this document is to provide

More information

Prescription Opioids

Prescription Opioids What are prescription opioids? Prescription Opioids Opioids are a class of drugs naturally found in the opium poppy plant. Some prescription opioids are made from the plant directly, and others are made

More information

Aetna s Initiative on the Opioid Epidemic

Aetna s Initiative on the Opioid Epidemic Aetna s Initiative on the Opioid Epidemic Christopher James D.O., M.P.H. Medical Director, BH- Mid-Atlantic Territory (JamesC1@aetna.com) July 23, 2017 HHS Data on Epidemic Every Day in the U.S. More than

More information

Naloxone. Medical Uses. Opiate overdose. From Wikipedia, the free encyclopedia. Naloxone

Naloxone. Medical Uses. Opiate overdose. From Wikipedia, the free encyclopedia. Naloxone Naloxone From Wikipedia, the free encyclopedia Naloxone Naloxone, sold under the brandname Narcan among others, is a medication used to reverse the effects of opioids, especially in overdose. [2] Naloxone

More information

Addressing the Opioid Epidemic Naloxone and its Role in Prevention of Opioid Overdose Death May 24, 2018

Addressing the Opioid Epidemic Naloxone and its Role in Prevention of Opioid Overdose Death May 24, 2018 Addressing the Opioid Epidemic Naloxone and its Role in Prevention of Opioid Overdose Death May 24, 2018 Five Pillars Today s Speaker Elizabeth Skoy, PharmD Associate Professor of Pharmacy Practice North

More information

OHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS

OHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS OHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS DEFINITIONS Opiate- originate from naturally-occurring elements found in the opium poppy plant. These drugs are

More information

Campus Narcan Project OPIOID OVERDOSE FIRST RESPONDER TRAINING

Campus Narcan Project OPIOID OVERDOSE FIRST RESPONDER TRAINING Campus Narcan Project OPIOID OVERDOSE FIRST RESPONDER TRAINING Opioid Epidemic Prescription Opiods Can be prescribed by doctors to treat moderate to severe pain, but can also have serious risks and side

More information

The Opioid Crisis URBAN FIRE FORUM SEPTEMBER 20-22, 2017

The Opioid Crisis URBAN FIRE FORUM SEPTEMBER 20-22, 2017 The Opioid Crisis URBAN FIRE FORUM SEPTEMBER 20-22, 2017 Every day in the United States, 144 people die as a result of an opioid overdose. Prescription drug abuse is the fastest growing drug problem in

More information

Naloxone Administration Training

Naloxone Administration Training Naloxone Administration Training Welcome! Welcome to the online training for naloxone administration The Presenter Dr. Joe Parks, Medical Director, Distinguished Professor, Missouri Institute for Mental

More information

OVERVIEW. NCHRC Harm Reduction Pills Ingestion to Smoking/Injecting Harm Reduction Legislation, Services and Advocacy Ban the Box/Fair Hiring LEAD Q+A

OVERVIEW. NCHRC Harm Reduction Pills Ingestion to Smoking/Injecting Harm Reduction Legislation, Services and Advocacy Ban the Box/Fair Hiring LEAD Q+A OVERVIEW NCHRC Harm Reduction Pills Ingestion to Smoking/Injecting Harm Reduction Legislation, Services and Advocacy Ban the Box/Fair Hiring LEAD Q+A North Carolina Harm Reduction Coalition (NCHRC) is

More information

Figure 1. National Drug Overdose Deaths Number Among All Ages, by Gender,

Figure 1. National Drug Overdose Deaths Number Among All Ages, by Gender, Figure 1. National Drug Overdose Deaths Number Among All Ages, by Gender, -217 1, Total Overdose Deaths Male Female 8, 7,237 6, 4, 16,849 2 21 22 23 24 36,1 25 26 27 28 29 21 211 212 213 214 215 216 217-217

More information

There are no financial or other pertinent conflicts of interest to disclose. Learning Objectives: Key Questions To Ask 10/4/2014

There are no financial or other pertinent conflicts of interest to disclose. Learning Objectives: Key Questions To Ask 10/4/2014 Maintaining Patient Safety When Chronic Opioid Therapy Is Prescribed P. David Pacheco, Ph.C, PA-C, CAAAPM Pain Medication Management Specialist Southwest Interventional Pain Specialists, PC 4700 Jefferson

More information

OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC:

OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: Cuyahoga County Board of Health OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: NOVEMBER 5, 2014 CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS DEFINITIONS Opiate- originate from naturally-occurring elements

More information

Project Lazarus Focus on Preventing Overdoses in Children: Presentation to Child Fatality Task Force, August 29, 2011 Catherine (Kay) Sanford, msph

Project Lazarus Focus on Preventing Overdoses in Children: Presentation to Child Fatality Task Force, August 29, 2011 Catherine (Kay) Sanford, msph Project Lazarus Focus on Preventing Overdoses in Children: Presentation to Child Fatality Task Force, August 29, 2011 Catherine (Kay) Sanford, msph Slides available upon request from www.projectlazarus.org.

More information

Opioid Use Disorders &Medication Treatment

Opioid Use Disorders &Medication Treatment Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review

More information

Cynthia B. Jones, Director Department of Medical Assistance Services (DMAS)

Cynthia B. Jones, Director Department of Medical Assistance Services (DMAS) Department of Medical Assistance Services 600 East Broad Street, Suite 1300 Richmond, Virginia 23219 MEDICAID MEMO http://www.dmas.state.va.us TO: All Prescribing Providers, Pharmacists, and Managed Care

More information

Overdose Prevention: Empowering School Personnel & Families

Overdose Prevention: Empowering School Personnel & Families Overdose Prevention: Empowering School Personnel & Families Christopher Welsh M.D. University of Maryland School of Medicine NCADD-Maryland Scientific Advisory Committee INITIATION OF DRUG USE >12 Y.O.(2013;

More information

Best Practices and Foundation Forum. Fred Wells Brason II

Best Practices and Foundation Forum. Fred Wells Brason II Best Practices and Foundation Forum Fred Wells Brason II fbrason@projectlazarus.org Wilkes County, NC Manual labor dominates employment options in this county of 69,000. Wilkes 4 Marvelous M s Moonshine

More information

PL CE LIVE: Overdose Prevention with Naloxone Opportunities for Pharmacists May 2015

PL CE LIVE: Overdose Prevention with Naloxone Opportunities for Pharmacists May 2015 PL CE LIVE: Overdose Prevention with Naloxone Opportunities for Pharmacists May 2015 Supplemental Information Background Most people who abuse prescription opioids get them for free from a friend or relative

More information

The Opioid Addiction Emergency In Virginia June 8, 2017

The Opioid Addiction Emergency In Virginia June 8, 2017 The Opioid Addiction Emergency In Virginia June 8, 2017 Marissa J. Levine, MD MPH State Health Commissioner Virginia Department of Health Chronic Disease of Addiction Definition: A primary, chronic disease

More information

Opioid education programs and nasal naloxone rescue kits

Opioid education programs and nasal naloxone rescue kits Opioid education programs and nasal naloxone rescue kits Arne Skulberg PhD student NTNU Consultant Anaesthetist, Oslo Epidemiology Europe 2 Epidemiology US 200 % increase in opioid overdoses since 2000.

More information

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative John W. McIlveen, Ph.D., LMHC, State Opioid Treatment Authority, Oregon Health Authority, Addictions and Mental Health Division

More information

Presentation at National Academies of Sciences Engineering Medicine

Presentation at National Academies of Sciences Engineering Medicine FOCUSED ON ADDICTION Presentation at National Academies of Sciences Engineering Medicine 11 th October 2017 COI statement Full time employee of Opiant Pharmaceuticals Inc. Shareholder of Opiant Pharmaceuticals

More information

Michael M. Miller, MD, FASAM, FAPA

Michael M. Miller, MD, FASAM, FAPA Michael M. Miller, MD, FASAM, FAPA mmiller@rogershospital.org Medical Director, Herrington Recovery Center (HRC) Rogers Memorial Hospital Oconomowoc, Wisconsin Vice Speaker Wisconsin Medical Society Clinical

More information

Pennsylvania DEPARTMENT OF HEALTH

Pennsylvania DEPARTMENT OF HEALTH Pennsylvania DEPARTMENT OF HEALTH Updated: 01/10/2018 XI. XII. KEY INFORMATION 1. If you believe, someone is experiencing an opioid overdose, call 911! 2. Remain with the person until first responders

More information

Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina

Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina Robert B. Hanlin, M.D., FAAFP Vice Chair, Medical Staff Affairs Greenville Health System Greenville, SC Disclosures

More information

PREVENTING OPIATE OVERDOSES IN SCHOOLS. Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region

PREVENTING OPIATE OVERDOSES IN SCHOOLS. Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region PREVENTING OPIATE OVERDOSES IN SCHOOLS Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region WHY IS THIS EVEN A QUESTION FOR SCHOOLS? In 2014, 467,000

More information

Naloxone Intranasal EMT OPTIONAL SKILL. Cell Phones and Pagers. Course Outline 09/2017

Naloxone Intranasal EMT OPTIONAL SKILL. Cell Phones and Pagers. Course Outline 09/2017 EMT OPTIONAL SKILL Naloxone Intranasal Cell Phones and Pagers Be courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off. Course Outline Introduction and Overview

More information

Mainstreaming naloxone rescue kits from harm reduction programs to pharmacies, police and fire responders

Mainstreaming naloxone rescue kits from harm reduction programs to pharmacies, police and fire responders Mainstreaming naloxone rescue kits from harm reduction programs to pharmacies, police and fire responders Alexander Y. Walley, MD, MSc Boston University School of Medicine ThINC Bergen 2015 Conference

More information

Prescription for Disaster: Impact of Drugs in our Society

Prescription for Disaster: Impact of Drugs in our Society Prescription for Disaster: Impact of Drugs in our Society What you can do about the epidemic of drug abuse in our communities 1 Florida Poison Information Center-Tampa 10/26/2012 Cynthia R. Lewis-Younger,

More information

Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic

Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention Understanding the Epidemic When the Prescription Becomes the Problem In a period of nine months, a tiny Kentucky county

More information

How to Save a Life: Naloxone for the Treatment of Opioid Overdose

How to Save a Life: Naloxone for the Treatment of Opioid Overdose How to Save a Life: Naloxone for the Treatment of Opioid Overdose Brandon Antinopoulos, PharmD PGY1 Community Practice Resident University of Pittsburgh School of Pharmacy & Pennsylvania Pharmacists Association

More information